Before 2013, there were hundreds of clinical trials done in India that resulted in faulty data, lawsuits, and significant problems. From 2013 to 2019, the number of clinical trials in India dropped significantly. However, in 2019, India implemented New Drug and Clinical Trial Rules.
This new regulation has helped jump-start an increase in clinical trials taking place in India today. Both the number of clinical sites and the number of investigators have almost doubled over the last few years. Given India’s large population, most clinical trials today are in infectious diseases, rare diseases, and cancer. In addition, the time to complete clinical trials has also been reduced. Finally, many trial participants now feel the quality coming from Indian clinical trials is a lot better than it used to be.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.
Source used in the article:https://www.livemint.com/companies/news/clinical-trials-in-india-grow-10-fold-post-pandemic-11684775241273.html